查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924754

口服羥乙基澱粉市場依適應症、規格、通路、劑型、最終用戶、包裝類型和患者年齡層分類－2026-2032年全球預測

Sodium Oxybate Oral Medications Market by Indication, Strength, Distribution Channel, Dosage Form, End User, Packaging Type, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年口服羥維鈉市場規模為 17 億美元，預計到 2026 年將成長至 18.4 億美元，到 2032 年將達到 28.8 億美元，複合年成長率為 7.80%。

關鍵市場統計數據
基準年 2025 17億美元
預計年份：2026年 18.4億美元
預測年份 2032 28.8億美元
複合年成長率 (%) 7.80%

口服氧合鈉療法概述：簡要概述其臨床作用、法規環境、相關人員優先事項以及對醫療保健服務的影響

本執行摘要介紹了口服氧氟沙星鈉療法在臨床實踐、監管路徑和相關人員等更廣泛背景下的應用。該治療方法在治療中樞性嗜睡症方面佔據著獨特的地位，其治療特性持續影響睡眠專家、神經科和多學科醫療團隊的處方行為。臨床療效、安全性考量以及以病人為中心的劑量需求，共同構成了臨床醫生和負責人面臨的複雜決策領域。

關鍵臨床證據、監管審查、供應鏈韌性和病患體驗創新正在重塑 Oxyvert 鈉市場格局和相關人員策略

近期發生的變革性變化改變了臨床和商業性相關人員對口服氧敏劑療法的認知、應用和理解。臨床方面，發作性睡病亞型和特發性嗜睡症診斷準確性的提高推動了針對性治療方案的討論，而對罕見症候群的仿單標示外適應症用藥的探索則凸顯了尚未滿足的醫療需求，這些需求正在影響著研究方向。這些變化促使臨床試驗設計進行調整，更加重視病患報告結局、長期安全性監測和真實世界療效評估。

評估2025年美國關稅變化對鈉氧變質劑供應鏈及相關人員應對能力的累積營運和商業影響

2025年美國關稅政策變化帶來的綜合影響，為Oxyvert Pharmaceuticals的製造商、經銷商和醫療保健採購商帶來了多重考慮。進口關稅和歸類規則的變更增加了原料採購和成品分銷的行政複雜性，迫使商業部門重新評估供應商合約和庫存策略。因此，一些製造商正在加快推動部分生產流程的在地化，或尋找能夠降低關稅波動風險的替代採購途徑。

關鍵細分洞察揭示了按適應症和亞型、劑量強度偏好、通路、劑型、最終用戶、包裝和年齡層分類的臨床隊列

細緻的市場細分框架揭示了影響羥乙基澱粉鈉使用情況的不同臨床路徑、劑量偏好、分銷網路和患者支持需求。在考慮臨床適應症時，市場主要圍繞著特發性嗜睡症、發作性睡病以及某些仿單標示外用藥。發作性睡病本身又分為 1 型和 2 型，而仿單標示外用藥則包括一些罕見病例，例如克萊恩-勒溫症候群，每種情況都有不同的臨床管理通訊協定和監測強度。這些基於適應症的差異會影響處方量、所需的安全性監測以及臨床醫生對生產者和專科藥房提供的輔助服務的期望。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和需求因素將影響氧氟沙星鈉的取得、分銷和臨床應用模式。

區域趨勢對氧氟沙星鈉療法的生產、分銷、報銷和處方方式有顯著影響。在美洲，完善的專科藥房網路、成熟的支付方體係以及集中的臨床專家中心，推動了專科醫生對該療法的快速接受，並促進了先進的患者支持模式的建立；同時，監管流程也強調了核准資料，並與區域支付方和衛生技術評估機構進行溝通。

競爭與合作並存的公司洞察，重點在於研發重點、生命週期管理策略、經銷夥伴以及影響鈉氧維特商業化的真實世界證據工作。

在氧氟沙星鈉領域，各公司層級的策略體現了創新、生命週期管理、監管事務和商業性夥伴關係的平衡。主要企業正致力於透過累積擴大適應症的證據、投資長期安全性數據以及加強患者支持體系來提升臨床差異化。同時，旨在延長產品生命週期的企業則專注於最佳化劑型和給藥方案、創新包裝以提高患者依從性，並與專業經銷商建立戰略合作夥伴關係以確保獲得優先通路。

為行業領導者提供切實可行的建議，以加強監管準備、供應鏈韌性、患者准入計劃和證據生成，從而確保永續的競爭優勢。

產業領導者應採取一系列合作措施，以應對監管的複雜性，強化供應鏈，最佳化患者用藥途徑，並加速具有臨床意義的創新。首先，應協調監管和藥物監測能力，以預測上市後數據需求，並簡化標籤完善流程，使其反映真實世界的安全性和有效性觀察結果。其次，應投資於多種關鍵原料來源，並考慮建立區域性生產合作夥伴關係，以在降低關稅和物流風險的同時，維持供應的連續性。

為了確保分析的嚴謹性，我們採用了調查方法，結合了對臨床醫生和供應鏈相關人員的初步訪談、二手文獻綜合、分銷圖譜和多方面的檢驗。

本執行摘要的研究工作包括與關鍵相關人員的直接對話，以及嚴謹的二手證據綜合和業務流程圖繪製。主要研究內容包括對睡眠醫學和神經病學臨床醫生、醫院和專科藥房系統的採購人員以及製造商和經銷商的供應鏈經理進行結構化訪談，以了解實際運營中的限制和臨床實踐模式。這些定性研究結果與已發布的監管文件、臨床指南、同行評審文獻和產品標籤進行系統性的三角驗證，以檢驗觀察到的趨勢並確保臨床準確性。

最終綜合策略意義，整合臨床證據、營運韌性和以病人為中心的護理服務，以指南氧合鈉治療的相關人員。

總之，口服氧氟沙星療法屬於獨特的治療領域，需要製定整合臨床證據開發、監管合規、營運韌性和病患體驗設計的策略。成功的相關人員將是那些能夠協調這些領域的人員：他們確保強力的安全監測和適應症特異性證據能夠增強臨床醫生的信心，多樣化的生產和分銷策略能夠確保供應的連續性，而個性化的患者支持計劃能夠解決給藥、劑量和依從性方面的實際挑戰。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 口服羥乙基澱粉市場依適應症分類

  • 特發性嗜睡症
  • 嗜睡症
    • 1 型嗜睡症
    • 2型嗜睡症
  • 仿單標示外用藥
    • 克萊恩-萊文症候群

9. 依強度分類的口服羥乙基澱粉市場

  • 4.5克
  • 9克
  • 7.5克
  • 6克

第10章 按通路分類的口服羥乙基澱粉市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第11章 口服羥乙基澱粉市場（依劑型分類）

  • 液體
  • 粉末

第12章 口服羥乙基澱粉市場（依最終用戶分類）

  • 居家醫療
  • 醫院
  • 專科診所

第13章 依包裝類型分類的羥乙基澱粉口服藥物市場

  • 多份
  • 單一劑量

第14章 依患者年齡層別分類的口服羥乙基澱粉市場

  • 成人
  • 兒童

第15章 口服羥乙基澱粉市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 口服羥乙基澱粉市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國口服羥乙基澱粉市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

18. 美國口服羥乙基澱粉市場

第19章 中國口服羥乙基澱粉市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alembic Pharmaceuticals Limited
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Labs Limited
  • Hikma Pharmaceuticals PLC
  • Jazz Pharmaceuticals plc
  • Lannett Company, Inc.
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Mylan NV
  • Natco Pharma Limited
  • Novartis AG
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-7A380DA7C47D

The Sodium Oxybate Oral Medications Market was valued at USD 1.70 billion in 2025 and is projected to grow to USD 1.84 billion in 2026, with a CAGR of 7.80%, reaching USD 2.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.70 billion
Estimated Year [2026] USD 1.84 billion
Forecast Year [2032] USD 2.88 billion
CAGR (%) 7.80%

A concise introduction to oral sodium oxybate therapies outlining clinical roles, regulatory context, stakeholder priorities, and implications for care delivery

This executive summary introduces oral sodium oxybate therapeutics within the broader context of clinical practice, regulatory pathways, and stakeholder priorities. The treatment class occupies a distinct niche in the management of central disorders of hypersomnolence, and its therapeutic profile continues to shape prescribing behavior among sleep specialists, neurologists, and interdisciplinary care teams. Clinical efficacy, safety considerations, and patient-centric administration requirements combine to form a complex decision space for clinicians and procurement professionals alike.

Regulatory oversight and product lifecycle management are central determinants of how sodium oxybate products reach and remain in clinical use. Post-approval requirements, risk mitigation strategies, and labeling considerations influence both commercial approaches and patient monitoring protocols. At the same time, payer policies and reimbursement frameworks affect access and adherence, prompting manufacturers and providers to innovate around support services and patient education.

Finally, evolving patient expectations and care delivery models are reshaping how therapies are administered and supported. Advances in telemedicine, home-based care models, and specialty pharmacy services are reducing barriers to initiation and ongoing management, while patient advocacy groups and clinical guidelines continue to refine appropriate use. Taken together, these elements set the stage for deeper analyses of market morphology, segmentation, and regional dynamics that follow in this report.

Major clinical evidence, regulatory scrutiny, supply chain resilience, and patient experience innovations that are reshaping the sodium oxybate landscape and stakeholder strategies

Recent transformational shifts have altered how oral sodium oxybate therapies are developed, delivered, and perceived across clinical and commercial stakeholders. Clinically, expanding diagnostic clarity for narcolepsy subtypes and idiopathic hypersomnia has prompted more targeted therapeutic discussions, while off-label explorations for rare syndromes have highlighted unmet clinical needs that influence research agendas. These shifts have spurred a recalibration of clinical trial design, with more emphasis on patient-reported outcomes, long-term safety monitoring, and real-world effectiveness measures.

On the regulatory front, heightened scrutiny of risk evaluation and mitigation strategies has prompted manufacturers to strengthen pharmacovigilance frameworks and to invest in prescriber education programs. Concurrently, supply chain resilience has become a strategic imperative following global disruptions, motivating producers and distributors to diversify sourcing, increase inventory buffers, and pursue regional manufacturing partnerships to reduce single-source vulnerabilities.

Patient experience innovations have also transformed market dynamics. Home-based dosing protocols, enhanced patient support services, and digital adherence tools have reduced friction in long-term management, while specialty pharmacy integration has improved coordination across care teams. Taken together, these transformative shifts have created a landscape where clinical evidence, regulatory alignment, operational resilience, and patient-centric delivery models now converge to determine competitive advantage.

Assessing the cumulative operational and commercial implications of United States tariff changes in 2025 on sodium oxybate supply chains and stakeholder resilience

The aggregate effects of tariff policy changes implemented in the United States during 2025 have introduced layered considerations for manufacturers, distributors, and healthcare purchasers of sodium oxybate formulations. Alterations in import tariffs and classification rules have increased the administrative complexity around raw material sourcing and finished-product movement, prompting commercial teams to reassess supplier contracts and inventory strategies. As a result, several manufacturers have accelerated efforts to localize certain manufacturing steps or to identify alternative sourcing corridors that mitigate exposure to tariff volatility.

Procurement teams and specialty distributors have adapted by tightening contractual terms and by embedding tariff contingency clauses into supplier agreements. These adjustments have required closer collaboration across legal, regulatory, and supply chain functions to ensure compliance while preserving continuity of supply. Payers and hospital systems have responded by emphasizing procurement predictability and by incorporating supply risk considerations into formulary decisions and contracting frameworks.

In parallel, regulatory and customs authorities have increased documentation requirements for pharmaceutical shipments, leading to incremental administrative workloads for commercial operations. Stakeholders have therefore invested in enhanced compliance capabilities and in scenario planning to preserve access for clinically vulnerable populations. Collectively, these developments underscore the need for integrated commercial and operational strategies that anticipate tariff-related disruptions and proactively secure uninterrupted therapy availability.

Key segmentation insights that illuminate clinical cohorts by indication and subtype, dosing strength preferences, distribution channels, dosage forms, end users, packaging formats, and age groups

A nuanced segmentation framework reveals differentiated clinical pathways, dosing preferences, distribution footprints, and patient support needs that shape sodium oxybate utilization. When considering clinical indication, the market is observed through idiopathic hypersomnia, narcolepsy, and selected off-label use; narcolepsy itself divides into type one and type two subgroups, while off-label applications include rare presentations such as Kleine Levin syndrome, each with distinct clinical management protocols and monitoring intensity. These indication-based distinctions affect prescribing volumes, required safety surveillance, and the nature of ancillary services clinicians expect from manufacturers and specialty pharmacies.

Strength-based segmentation captures clinical and convenience trade-offs among available dosages, spanning four point five gram, six gram, seven point five gram, and nine gram formulations. Differences in strength translate into varied dosing schedules, patient tolerance profiles, and refill cadence, which in turn influence adherence support models and distribution strategies. Distribution channel segmentation differentiates hospital pharmacies, online pharmacies, retail pharmacies, and specialty pharmacies, creating multiple access pathways that carry distinct regulatory obligations, patient counseling norms, and reimbursement interactions.

Dosage form distinctions between liquid and powder presentations affect administration complexity and patient preference, while end user segmentation-home care, hospitals, and specialty clinics-illustrates the operational contexts for delivery and monitoring. Packaging type, whether multi dose or single dose, further influences convenience, waste management, and adherence patterns. Finally, patient age group segmentation into adults and pediatrics highlights divergent safety monitoring, dosing considerations, and caregiver engagement requirements. Integrating these segmentation lenses enables stakeholders to pinpoint intervention points for clinical support, supply planning, and targeted commercialization.

Regional dynamics and demand drivers across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine access, distribution, and clinical adoption patterns for sodium oxybate

Regional dynamics exert a powerful influence on how sodium oxybate therapies are manufactured, distributed, reimbursed, and prescribed. In the Americas, well-established specialty pharmacy networks, mature payer systems, and concentrated centers of clinical expertise drive both rapid adoption among specialized providers and sophisticated patient support models, while regulatory processes emphasize robust post-authorization safety oversight. Transitioning to Europe, Middle East & Africa, stakeholders encounter a heterogeneous patchwork of regulatory regimes, reimbursement frameworks, and access pathways that require tailored market entry and commercialization approaches, including local dossier adaptations and engagement with regional payers and health technology assessment bodies.

Across the Asia-Pacific region, accelerating diagnostic capacity and expanding specialist networks are increasing awareness and demand for hypersomnolence therapies, but variations in local manufacturing capacity, import regulations, and distribution infrastructure necessitate flexible supply strategies. In each region, differences in hospital formulary processes, specialty clinic penetration, and home-care adoption rates affect where and how treatments are dispensed. Cross-regional learning offers opportunities: successful patient support models in one geography can be adapted to others, and collaborative manufacturing arrangements can smooth regional supply imbalances.

Consequently, strategic plans that marry global clinical evidence with region-specific operational and reimbursement realities will enable manufacturers and providers to improve access and deliver consistent patient outcomes across these diverse markets.

Competitive and collaborative company insights highlighting R&D priorities, lifecycle management strategies, distribution partnerships, and real-world evidence initiatives shaping sodium oxybate commercialization

Company-level strategies in the sodium oxybate space reflect a balance of innovation, lifecycle management, regulatory navigation, and commercial partnerships. Leading developers emphasize clinical differentiation through expanded indication evidence, investments in long-term safety data, and enhancements to patient support ecosystems. Concurrently, organizations pursuing lifecycle extension focus on formulation optimization across strengths and dosage forms, packaging innovations to improve adherence, and strategic alliances with specialty distributors to secure preferred channel placements.

Across the competitive landscape, collaboration between manufacturers and specialty pharmacies has emerged as a common mechanism to streamline access and to deliver high-touch patient education and monitoring programs. Strategic licensing and co-commercialization agreements permit faster regional entry while sharing regulatory and market-development burdens. Firms seeking to secure supply continuity prioritize diversified raw material sourcing and manufacturing redundancy, often through contract manufacturing partnerships or regional production nodes.

Moreover, companies are increasingly leveraging real-world evidence programs to support clinical value propositions and to inform payer conversations. These initiatives often integrate digital adherence tools and patient-reported outcome collection to demonstrate long-term benefit and to underpin access negotiations with payers and integrated delivery networks. Taken together, these company-level approaches delineate practical pathways to strengthen market position while addressing clinician and patient expectations.

Actionable recommendations for industry leaders to strengthen regulatory preparedness, supply resilience, patient access programs, and evidence generation to secure sustainable competitive advantage

Industry leaders should pursue a set of coordinated actions to manage regulatory complexity, fortify supply chains, optimize patient access, and accelerate clinically meaningful innovation. First, align regulatory and pharmacovigilance capabilities to anticipate post-market data requirements and to streamline label refinements that reflect real-world safety and effectiveness observations. Second, invest in multi-sourcing for critical raw materials and consider regional manufacturing partnerships to mitigate tariff and logistics exposure while preserving continuity of supply.

Third, design differentiated patient support models that accommodate the clinical heterogeneity defined by indication subtypes, strength preferences, and age groups; these models should integrate specialty pharmacy workflows, telehealth touchpoints, and caregiver education for pediatric contexts. Fourth, map distribution strategies to channel dynamics, recognizing that hospital pharmacies, retail outlets, online pharmacies, and specialty pharmacies each play distinct roles in access and adherence, and structure contractual relationships to ensure predictable supply and appropriate clinical oversight.

Fifth, generate and deploy targeted real-world evidence campaigns that substantiate long-term outcomes, inform payer discussions, and support differentiated positioning against competitive alternatives. Lastly, incorporate scenario planning for tariff, regulatory, and supply-chain disruptions into commercial forecasting and contracting to preserve access for vulnerable patient groups. Executed together, these steps create resilient, patient-focused strategies that support sustainable growth and improved clinical outcomes.

Methodology and evidence approach combining primary clinician and supply chain interviews, secondary literature synthesis, distribution mapping, and multi-source triangulation to ensure analytical rigor

The research underpinning this executive summary combined primary stakeholder engagement with rigorous secondary evidence synthesis and operational mapping. Primary inputs included structured interviews with clinicians specializing in sleep medicine and neurology, procurement leads from hospital and specialty pharmacy systems, and supply chain managers from manufacturers and distributors to capture real-world operational constraints and clinical practice patterns. These qualitative insights were systematically triangulated with publicly available regulatory documents, clinical guidelines, peer-reviewed literature, and product labels to validate observed trends and to ensure clinical accuracy.

Operational analyses mapped manufacturing pathways, raw material dependencies, and logistics corridors to identify potential vulnerabilities and mitigation strategies. Distribution channel assessment integrated interviews with hospital pharmacy directors, specialty pharmacy managers, and online pharmacy operators to clarify differences in dispensing protocols, counseling responsibilities, and reimbursement interactions. The methodology also incorporated a rigorous document review of post-marketing safety communications and risk management plans to align company practices with regulatory expectations.

Throughout the research process, findings were corroborated across multiple sources to reduce bias, and synthesis emphasized actionable implications for clinical practice, supply-chain management, and commercial strategy. The result is a consolidated evidence base that supports pragmatic recommendations while maintaining transparency about data sources and analytical limitations.

Concluding synthesis of strategic implications that unify clinical evidence, operational resilience, and patient-centered delivery to guide stakeholders in sodium oxybate therapeutics

In conclusion, oral sodium oxybate therapies occupy a specialized therapeutic space that demands integrated strategies across clinical evidence development, regulatory alignment, operational resilience, and patient experience design. Successful stakeholders will be those who harmonize these domains-ensuring that robust safety monitoring and indication-specific evidence support clinician confidence, that diversified manufacturing and distribution strategies preserve continuity of supply, and that tailored patient support programs address the practicalities of dosing, administration, and adherence.

Regional heterogeneity and tariff-related operational complexities underscore the importance of flexible market-entry planning and proactive supply-chain management. At the same time, segmentation by indication, strength, distribution channel, dosage form, end user, packaging type, and patient age group reveals nuanced opportunities to tailor offerings and support services to discrete clinical and operational needs. Companies that commit resources to real-world evidence generation, specialty pharmacy partnerships, and targeted patient engagement will be better positioned to meet clinician expectations and to navigate payer dialogues.

Ultimately, the convergence of clinical innovation, operational agility, and patient-centered delivery models will determine long-term success in this space, enabling improved outcomes for patients living with disorders of hypersomnolence while supporting sustainable commercialization pathways for sponsors and providers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sodium Oxybate Oral Medications Market, by Indication

  • 8.1. Idiopathic Hypersomnia
  • 8.2. Narcolepsy
    • 8.2.1. Type One Narcolepsy
    • 8.2.2. Type Two Narcolepsy
  • 8.3. Off-Label Use
    • 8.3.1. Kleine Levin Syndrome

9. Sodium Oxybate Oral Medications Market, by Strength

  • 9.1. Four Point Five Gram
  • 9.2. Nine Gram
  • 9.3. Seven Point Five Gram
  • 9.4. Six Gram

10. Sodium Oxybate Oral Medications Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Specialty Pharmacies

11. Sodium Oxybate Oral Medications Market, by Dosage Form

  • 11.1. Liquid
  • 11.2. Powder

12. Sodium Oxybate Oral Medications Market, by End User

  • 12.1. Home Care
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Sodium Oxybate Oral Medications Market, by Packaging Type

  • 13.1. Multi Dose
  • 13.2. Single Dose

14. Sodium Oxybate Oral Medications Market, by Patient Age Group

  • 14.1. Adults
  • 14.2. Pediatrics

15. Sodium Oxybate Oral Medications Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Sodium Oxybate Oral Medications Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Sodium Oxybate Oral Medications Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Sodium Oxybate Oral Medications Market

19. China Sodium Oxybate Oral Medications Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Alembic Pharmaceuticals Limited
  • 20.6. Amneal Pharmaceuticals, Inc.
  • 20.7. Aurobindo Pharma Limited
  • 20.8. Cipla Limited
  • 20.9. Dr. Reddy's Laboratories Ltd.
  • 20.10. Glenmark Pharmaceuticals Ltd.
  • 20.11. Hetero Labs Limited
  • 20.12. Hikma Pharmaceuticals PLC
  • 20.13. Jazz Pharmaceuticals plc
  • 20.14. Lannett Company, Inc.
  • 20.15. Lupin Limited
  • 20.16. Macleods Pharmaceuticals Ltd.
  • 20.17. Mylan N.V.
  • 20.18. Natco Pharma Limited
  • 20.19. Novartis AG
  • 20.20. Strides Pharma Science Limited
  • 20.21. Sun Pharmaceutical Industries Ltd.
  • 20.22. Teva Pharmaceutical Industries Ltd.
  • 20.23. Torrent Pharmaceuticals Ltd.
  • 20.24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY IDIOPATHIC HYPERSOMNIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY IDIOPATHIC HYPERSOMNIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY IDIOPATHIC HYPERSOMNIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY TYPE ONE NARCOLEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY TYPE ONE NARCOLEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY TYPE ONE NARCOLEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY TYPE TWO NARCOLEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY TYPE TWO NARCOLEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY TYPE TWO NARCOLEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY KLEINE LEVIN SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY KLEINE LEVIN SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY KLEINE LEVIN SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY FOUR POINT FIVE GRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY FOUR POINT FIVE GRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY FOUR POINT FIVE GRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NINE GRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NINE GRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NINE GRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SEVEN POINT FIVE GRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SEVEN POINT FIVE GRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SEVEN POINT FIVE GRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SIX GRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SIX GRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SIX GRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GCC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. GCC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 177. GCC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. GCC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 179. GCC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. G7 SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 207. G7 SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. G7 SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 209. G7 SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. G7 SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. NATO SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 215. NATO SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 217. NATO SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. NATO SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 219. NATO SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. NATO SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY NARCOLEPSY, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY OFF-LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA SODIUM OXYBATE ORAL MEDICATIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)